Celanese Corporation announced the launch of Glaukos’s iDose TR that uses the former’s VitalDose EVA to provide sustained drug release. Sustained drug delivery as an alternative to drops for glaucoma treatment addresses patient noncompliance.

FDA-approved late last year, iDose TR is an intracameral therapy designed to continuously deliver 24/7 therapeutic levels of a proprietary formulation of travoprost over an extended period. Two pivotal trials that included 1,150 patients demonstrated its safety and efficacy, according to a news release. VitalDose EVA creates a nanoporous membrane for travoprost delivery. According to the manufacturer, the platform can be formulated into a wide range of form factors to suit drug delivery needs for various conditions.

The VitalDose EVA Drug Delivery Platform provides reliable, controlled-release performance and has a long history of use in approved parenteral drug products in the United States and Europe, the release stated.